Advertisement

Advertisement

ARTV Stock Latest News

Artiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target

RatingsArtiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target

PremiumRatings

Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41

16d ago

Artiva Biotherapeutics files $400M mixed securities shelf

PremiumThe Fly

Artiva Biotherapeutics files $400M mixed securities shelf

17d ago

Artiva Biotherapeutics reports Q2 EPS (63c), consensus (64c)

PremiumThe Fly

Artiva Biotherapeutics reports Q2 EPS (63c), consensus (64c)

17d ago

Artiva Biotherapeutics Sets Deadline for 2026 Meeting

PremiumCompany Announcements

Artiva Biotherapeutics Sets Deadline for 2026 Meeting

1M ago

Fourteen new option listings and one option delisting on July 22nd

PremiumThe FlyFourteen new option listings and one option delisting on July 22nd

1M ago

Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026

The Fly

Artiva Biotherapeutics highlights AlloNK data presented at EULAR 2026

3M ago

Artiva Biotherapeutics Announces Major Executive Leadership Transitions

Company Announcements

Artiva Biotherapeutics Announces Major Executive Leadership Transitions

3M ago

Artiva Biotherapeutics price target raised to $41 from $18 at Needham

PremiumThe Fly

Artiva Biotherapeutics price target raised to $41 from $18 at Needham

3M ago

Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush

PremiumThe Fly

Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush

3M ago

Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial

PremiumRatings

Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial

3M ago

Artiva Biotherapeutics Announces $300 Million Equity Offering

PremiumCompany Announcements

Artiva Biotherapeutics Announces $300 Million Equity Offering

4M ago

Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright

PremiumThe FlyArtiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright

4M ago

Artiva Highlights AlloNK RA Data and Phase 3 Alignment

Company Announcements

Artiva Highlights AlloNK RA Data and Phase 3 Alignment

4M ago

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

The Fly

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

4M ago

Artiva reports data from clinical trials evaluating AlloNK

PremiumThe Fly

Artiva reports data from clinical trials evaluating AlloNK

4M ago

Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts

PremiumRatings

Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts

6M ago

Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating

PremiumRatings

Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating

6M ago

Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer

PremiumCompany Announcements

Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer

6M ago

Artiva Biotherapeutics appoints Huston as Chief Financial Officer

PremiumThe FlyArtiva Biotherapeutics appoints Huston as Chief Financial Officer

6M ago

Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board

Company Announcements

Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board

6M ago

Artiva Biotherapeutics appoints Sorg to board of directors

The Fly

Artiva Biotherapeutics appoints Sorg to board of directors

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >